Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Helps Launch Türkiye's First HIV Testing Week

Accesswire March 19, 2024

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Business Wire March 18, 2024

Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations

Accesswire March 12, 2024

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Business Wire March 11, 2024

Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing

Accesswire March 7, 2024

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Business Wire March 6, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Business Wire March 6, 2024

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Business Wire March 6, 2024

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Business Wire March 5, 2024

Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Business Wire March 5, 2024

Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area

Accesswire March 5, 2024

Gilead Sciences: National Black HIV/AIDS Awareness Day

Accesswire February 29, 2024

Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Accesswire February 28, 2024

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Business Wire February 27, 2024

U.S. FDA Approves Expanded Indication for Gilead's Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Business Wire February 26, 2024

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Business Wire February 26, 2024

Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change

Accesswire February 26, 2024

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire February 20, 2024

Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC

Accesswire February 20, 2024

Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies

Accesswire February 13, 2024